MILRINONE LACTATE INJECTION 1 MG — DIN 02244854
MILRINONE (MILRINONE LACTATE) : 1 MG · SANDOZ CANADA INCORPORATED · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MILRINONE LACTATE INJECTION?
MILRINONE LACTATE INJECTION 1 MG contains MILRINONE (MILRINONE LACTATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02244854, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MILRINONE LACTATE INJECTION used for?
Treatment of mild to moderate hypertension and prophylaxis of chronic stable angina pectoris.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Milrinone cost around the world?
Milrinone is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 3 | 3 | SAR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
9 pack listings across 9 brand entries and 6 price bases, refreshed 03 Sep 2026. Ranges span every Milrinone pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Milrinone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Milrinone, across 11 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 1 | 1 | MILRINONE LACTATE INJECTION, USP | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | MILRINONE LACTATE INJECTION USP | Sourceable in Canada |
| APOTEX INC | 1 | 0 | APO-MILRINONE INJECTABLE | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | MILRINONE LACTATE INJECTION | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | MILRINONE LACTATE INJECTION | No marketed DIN |
| JAMP PHARMA CORPORATION | 1 | 0 | MILRINONE LACTATE INJECTION, USP | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | MILRINONE LACTATE INJECTION | No marketed DIN |
| SANOFI-SYNTHELABO CANADA INC | 1 | 0 | PRIMACOR INJECTION 1MG/ML | No marketed DIN |
| STERIMAX INC | 1 | 0 | MILRINONE LACTATE INJECTION | No marketed DIN |
| STRIDES PHARMA CANADA INC | 1 | 0 | MILRINONE LACTATE INJECTION | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | MILRINONE INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Available in blister packs and bottles of 100 tablets. |
| Storage | Store between 15°C and 30°C. Protect from light and moisture. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Milrinone |
|---|---|
| ATC code | C01CE02 |
| AHFS class | 24:04.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02244854 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2244854 |
| Brand name | MILRINONE LACTATE INJECTION |
| Generic / active ingredient | MILRINONE (MILRINONE LACTATE) : 1 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | C01CE02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01CE |
| Current status | CANCELLED POST MARKET |
| Status date | 31-Jul-2025 |
| Original market date | 2003-06-25 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Chronic stable angina and hypertension: Starting dose 20 mg or 30 mg once daily. Maximum daily dose is 90 mg. Swallow whole; do not crush or chew.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to nifedipine; pregnancy, breastfeeding; cardiovascular shock; combination with rifampicin; severe aortic stenosis; unstable angina; acute MI.
Warnings and precautions
May cause severe hypotension, exacerbation of angina, or peripheral edema. Use with caution in patients with CHF or severe hepatic impairment. Avoid grapefruit juice.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MILRINONE LACTATE INJECTION USP | 1 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02521407 |
| MILRINONE LACTATE INJECTION, USP | 1 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02244622 |
| APO-MILRINONE INJECTABLE | 1.0 MG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | 02249820 |
| MILRINONE INJECTION | 1 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02244811 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | 02383519 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | EUGIA PHARMA INC. | APPROVED | 02538369 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | STERIMAX INC | APPROVED | 02447908 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | AURO PHARMA INC | DORMANT | 02470047 |
| MILRINONE LACTATE INJECTION, USP | 1 MG | SOLUTION | JAMP PHARMA CORPORATION | APPROVED | 02539543 |
| PRIMACOR INJECTION 1MG/ML | 1 MG | SOLUTION | SANOFI-SYNTHELABO CANADA INC | CANCELLED POST MARKET | 02006391 |
2 · Same class — other molecules in ATC C01CE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Milrinone | APO-MILRINONE INJECTABLE · MILRINONE INJECTION · MILRINONE LACTATE INJECTION · MILRINONE LACTATE INJECTION USP · +2 more | 11 | 2 | Yes |
| Amrinone | INOCOR LIQ 5MG/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01CA | Dobutamine · Dopamine · Ephedrine · Epinephrine · Epinephrine, Combinations · +6 more | 101 | 36 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MILRINONE LACTATE INJECTION called?
The same molecule, Milrinone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| MILRINONE | Latin | Lebanon |
| Milrinone BOS | Latin | Saudi Arabia |
| Milrinone Lactate | Latin | Iceland |
| PRIMACOR | Latin | Bahrain |
| Primalon | Latin | Saudi Arabia |
| RINOMEL | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.